Navigation Links
BioNeutral's Ygiene(TM) Achieves World's Fastest Kill Time With a 100% Total Spore Eradication Verified In Independent Sporicidal/Sterilant Test

NEWARK, N.J., Aug. 12 /PRNewswire-FirstCall/ -- BioNeutral Group, Inc. ("BioNeutral") (OTC Bulletin Board: BONU), a specialty chemical technology-based Life Science company announced today that ATS Labs using the EPA required AOAC Sporicidal Test with Ygiene(TM) Hospital Grade formula delivered a 100% Total Kill of over one million live Clostridium Sporogenes spores in a four (4) minute time frame - performance which is up to 75 times faster than competitive products such as Steris(R) Spor-Klenz RTU.

"The company is in discussions with a global leader in the health care sector to arrange distribution following our regulatory approval," said Stephen J. Browand, CEO BioNeutral Group Inc. "Our health care market alone is very broad and includes every hospital, nursing home, home health care patient, every immune suppressed patient, emergency room, ambulance, first responder, and doctor, dental, and veterinary office."

"Whether it is the present Swine Flu (H1N1) pandemic or the most difficult to kill dangerous organisms, Bioneutral's technology has given rise to the only family of sporicidal formulations for the hospital/health care sector, industry (including schools) and the home. Performance is unsurpassed, it has a Green environmental profile, is non corrosive, non staining to most fabrics (eg sheets and pillow cases) and can come into contact with skin while remaining sporicidal," said Dr Andy Kielbania PhD, BioNeutral's Chief Scientific Officer.

This EPA required AOAC Sporicidal Test utilizing spore impregnated knotted suture loops is an extremely difficult test to pass especially when starting with over one million Clostridium Sporogenes spores. The rapid elimination of these health threatening microorganisms at health care facilities will reduce the incidents of Hospital Acquired Infections (ACI) and the associated loss of lives. Many of today's best known industrial disinfectants, including those commonly used in hospitals and health care facilities, are unable to pass this test at all or require up to several hours of direct wet contact to pass.

Examples of commonly used antimicrobials in health care facilities which cannot claim passing this EPA sporicide/sterilant test include CaviCide(R) and Medica DC 10(TM). While these antimicrobials may eliminate easily eradicated bacteria and some viruses, they have no effect on spores and therefore cannot claim to be sporicidal. Examples of antimicrobials which have passed the EPA required test include Actril(R) Cold Sterilant and Clidox(R)(R)-S which require hours to be effective. Steris(R) Hydrogen Peroxide Sterilant requires special protective equipment and highly trained professionals to correctly apply this antimicrobial. In addition this product requires 90 minutes of direct contact to eliminate spores. Steris(R) Spor-Klenz RTU is easier to apply but can take up to five and one half hours (5.5 hours) to eliminate spores.

A sporicide/sterilant which operates at room temperature with the rapid kill demonstrated by Ygiene(TM) Hospital Grade will provide a substantial economic advantage for future users. Ygiene is easy to use and provides a much quicker turn around time for total sterilization of equipment and facilities. BioNeutral's Ygiene(TM) will reduce the cost of human resources and capital expenditure, decrease turnaround time for surgical procedures and medical facilities thereby maximizing precious resources while providing increased safety for staff and patients alike.

About ATS Labs:

ATS Labs, is a leading internationally recognized lab used by the developers and users of antimicrobial products. They provide comprehensive antimicrobial service and their superior client service and scientific data have earned them a distinguished record of acceptance with regulatory agencies in the U.S., Canada and the world.

About BioNeutral Group, Inc.

Headquartered at the New Jersey Institute of Technology/EDC in Newark, New Jersey, BioNeutral Group, Inc., is a chemical technology-based Life Science company that intends to commercialize a combinational chemistry-based technology which can neutralize harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. The formulations, including Ygiene(TM) and Ogiene(TM), which are eco-friendly and include natural and common ingredients which are found in baby products and in every day foods. The Company has combined these widely-used compounds in highly specialized ways to create products that dramatically enhance disinfecting and cleaning results; products include BioNeutralizers and ChemoNeutralizers. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications.

More information about the Company may be found at

Forward-Looking Statements

BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene(TM) and are not yet available for sale in the United States.

Contact Information

    BioNeutral Group Inc.
    Stephen J. Browand, President and CEO

    Investor Relations
    Aimee Boutcher
    973 239-2878

SOURCE BioNeutral Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Independent Laboratory Testing Shows BioNeutrals Hospital Grade Ygiene(TM) Eliminates Aspergillus Niger (Black Mold) Spores
2. Kingfisher Healthcare (KFH) Achieves World Class Quality Platform
3. Kaiser Permanente Achieves Climate Action Leader Status
4. OSF HealthCare Achieves Impressive Tobacco Quit Rates with the Free & Clear(R) Quit For Life(TM) Program
5. LMS integrated obstetrics solution achieves general availability
6. ENDEAVOR IV achieves primary endpoint, demonstrates similar safety profile compared to Taxus stent
7. Pharsight Achieves $7.3 Million in Quarterly Revenue
8. Halogen Software Achieves Most Successful Quarter in Company History - Includes Record Year-Over-Year Overall and License Revenue
9. Cethromycin achieves all endpoints in second pivotal Phase III Trial for treatment for pneumonia
10. Joint Commission International Achieves Accreditation from ISQua
11. TyraTech Achieves Insecticide Development and Financial Milestones With Partner Arysta LifeScience
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... the way that they are handling security in light of the recent terrorist attacks ... in an attempt to stop an attack from reaching U.S. soil. Especially around special ...
(Date:11/27/2015)... ... November 27, 2015 , ... An ... way to dispense prescription medications at home, so he invented the patent-pending ELECTRONIC ... and dispense prescription medications. In doing so, it could help to prevent potential ...
(Date:11/27/2015)... ... November 27, 2015 , ... The ... of USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with a ... component is distributed nationally, through a vast social media strategy and across a ...
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent with ... the 2016 Building Better Radiology Marketing Programs meeting will showcase some ... March 6, 2016, at Caesars Palace in Las Vegas with a pre-conference session ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you ... for not only fulfilling the needs of advisers and clients but going above ... and providing top-tier customer service. However, there's always room for improvement, which is ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... Nov. 25, 2015  The American Academy of ... (ACOG), and the March of Dimes cheered today,s ... Our Infants Act of 2015 (S.799), which ... newborns born exposed to drugs, such as opioids, ... introduction, all three organizations have worked together leading ...
(Date:11/25/2015)... ATLANTA , Nov. 25, 2015 ... the first federal bellwether trial against Wright Medical ... relating to their Conserve metal-on-metal hip implant device, ... Christiansen.  Following a two week trial and three ... Conserve metal-on-metal hip device was defectively designed and ...
(Date:11/25/2015)... November 25, 2015 Kitov Pharma ... (TASE: KTOV), a biopharmaceutical company focused on the development ... clinical conditions, today announced the closing of its previously ... ( ADSs ), each representing 20 ordinary shares of ... ADSs. The ADSs and warrants were issued in a ...
Breaking Medicine Technology: